LYA914 is an orally active AR/AR-V7 PROTAC degrader. It targets the proteolysis of the androgen receptors (AR) conserved DNA-binding domain (DBD). LYA914 demonstrates effective antiproliferative activity in Enzalutamide-insensitive or resistant cells and inhibits tumor growth in VCaP/LNCaP tumor mouse models. It is suitable for studying castration-resistant prostate cancer (CRPC).
Target-Kategorie:
PROTACs|||Androgen Receptor|||Akt
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
